Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From sublingual aspirin for cardiac emergencies to nanotech nutraceuticals, Aspire Biopharma Holdings Inc (ASBPW) packs its SEC reports with dense R&D data, patent timelines, and licensing clauses. Finding pivotal trial costs or breakthrough-therapy milestones inside a 300-page document can slow decision-making.
Stock Titan eliminates that bottleneck. Our AI reviews every Aspire Biopharma quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the instant they post to EDGAR. You receive:
- Plain-English digests—Aspire Biopharma SEC filings explained simply
- Alerts for Aspire Biopharma Form 4 insider transactions real-time, capturing executive stock transactions Form 4 within minutes
- Side-by-side earnings report filing analysis showing R&D spend, cash burn, and pipeline progress
Whether you’re tracking Aspire Biopharma insider trading Form 4 transactions ahead of clinical readouts, studying the proxy statement executive compensation to gauge dilution risk, or just understanding Aspire Biopharma SEC documents with AI, every disclosure is indexed here. Our coverage spans S-1 offerings, 13D activist positions, and all amendments—updated continuously so you never miss a detail.
The filing is a Definitive Proxy Statement for Aspire Biopharma Holdings, Inc. (ticker ASBPW) and includes shareholder voting materials and ownership details. The extract lists several named holders with specific share counts and ownership percentages, including Kraig T. Higginson at 10,531,193 shares representing 21.6% and a group or aggregate entry showing 12,797,468 shares or 25.8%. Other disclosed holdings include Surendra Ajjarapu with 1,121,736 shares (2.3%), Ernest J. Scheidemann, Jr. with 564,168 shares (1.1%), and smaller positions for Edward J. Kimball, Howard Doss, and Donald G. Fell (share counts shown; percentages marked with * in the extract). The document also includes standard proxy checkboxes and a company address in Estero, Florida, plus a reference to the Certificate of Incorporation. The content is a fragmentary excerpt focused on ownership and proxy logistics rather than financial results.
Aspire Biopharma Holdings, Inc. (ASBPW) S-1 describes the company’s IPO-related capital structure, Trust Account holdings, related-party financing and post-transaction balances following its business combination activity. The company completed a Unit offering that funded a Trust Account (approximately $294.7 million initially) and recorded redemptions that reduced Trust Account balances to $6.67 million at December 31, 2024 and thereafter to amounts described as held for a Business Combination. The filing discloses substantial subscription agreement loans, working capital loans, multiple original-issue-discount (OID) notes to related parties, and convertible/debt instruments with debt discounts and fair-value adjustments recorded as large non-cash charges. Management reports a working capital deficit and notes substantial doubt about the company’s ability to continue as a going concern without additional financing. The record shows issuance and conversion of multiple share classes, sponsor/affiliate commitments, warrant pools outstanding, and material related-party transactions and contingent fees tied to the Business Combination.
FAQ
What is the current stock price of Aspire Biopharma Holdings (ASBPW)?
